Massachusetts Pharmacists Association’s Post

📍Novo Nordisk diabetes drug Ozempic, known chemically as semaglutide, has shown promising results in a late-stage trial. 📍The drug slowed the worsening of kidney problems and reduced the risk of kidney failure, heart issues, stroke, and death in patients with type 2 diabetes. 📍The trial, which involved weekly 1-milligram injections, found that Ozempic cut the combined risk of these complications by 24% over 3.4 years compared to a placebo. #novonordisk #diabetes #healthmanagement #ozempic #semaglutide #clinicaltrails

#Semaglutide (Ozempic and Wegovy): Uses, Mechanism, and Potential Implications for Contraceptive Effectiveness #Semaglutide (marketed as Ozempic and Wegovy) is a medication primarily used to manage type 2 diabetes. It functions as a GLP-1 receptor agonist, which helps regulate blood sugar levels by stimulating insulin secretion and inhibiting glucagon release. #Recent_Applications_and_Mechanisms_of_Action Recently, semaglutide has garnered attention for its efficacy in promoting weight loss. The drug operates by: - Slowing gastric emptying. - Reducing appetite. - Increasing feelings of fullness. #Clinical_Efficacy Clinical trials have demonstrated that semaglutide can result in significant weight loss for individuals both with and without type 2 diabetes. #Dosage_for_Weight_Loss: The typical starting dose is 0.25 mg once weekly, with a gradual increase to 1 mg once weekly. For weight loss, higher doses, up to 2.4 mg weekly, have been studied. #Interaction_with_Oral_Contraceptives A noteworthy consideration is the potential interaction between semaglutide and oral contraceptives. Recent studies suggest that semaglutide may impact the absorption of oral contraceptives due to its effect on gastric emptying. This delayed gastric emptying may lead to lower plasma concentrations of contraceptives, potentially reducing their effectiveness. There have been reports, particularly among women with PCOS, of pregnancies occurring while using both Ozempic and oral contraceptives. This raises concerns about the reliability of oral contraceptives when used concurrently with semaglutide. #Conclusion If you are considering using Ozempic for weight loss or have concerns regarding its interactions with oral contraceptives, it is essential to consult with your prescribing physician to evaluate the risks and make informed decisions. #Sources: Clinical trials and studies on semaglutide vs weight loss.

Novo Nordisk’s new drug, CagriSema, is a promising treatment combining semaglutide and cagrilintide for type 2 diabetes and weight management. In phase 2 trials, CagriSema showed significant improvements in reducing A1C levels by 2.2%, body weight by 15.6%, and increasing time in range by 43% over 32 weeks. The combination therapy is administered as a once-weekly injection and has been found to be safe and well-tolerated. Novo Nordisk is advancing to phase 3 trials to further evaluate its efficacy and safety. Novo Nordisk’s blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer’s disease, according to a new analysis of electronic health records. The findings suggest that Ozempic and other GLP-1 treatments could potentially delay or prevent the memory-robbing condition in patients with diabetes. Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients compared with seven other diabetes medications. Contact us today, and let us demonstrate how we can elevate your portfolio to new levels Contact Us: bit.ly/AlgoTrader Website: alphabinwanicapital.com Free Newsletter: bit.ly/AlgoNewsletter #Investing #ThematicInvesting #AI #CagriSema

Exploring GLP-1 Drugs for Obesity: What to Know Before You Take Them Join our free webinar scheduled for tomorrow, November 13, with Veronica R. Johnson, MD. Medications to treat obesity have been around for over 50 years. However, the use of GLP-1 agonists has changed how people and their healthcare providers approach weight management. In this webinar, you’ll learn about GLP-1 agonists that can help with obesity treatment, the common side effects of these drugs, misunderstandings about their use, and more. Register: https://lnkd.in/ebWMf7XJ

Ozempic Gains FDA Approval for Chronic Kidney Disease Treatment in Diabetics : The FDA has approved Novo Nordisk’s Ozempic to treat chronic kidney disease in people with Type 2 diabetes, expanding its use beyond diabetes management. A major study showed Ozempic can slow kidney decline, lower the risk of heart-related deaths, and reduce severe kidney complications by 24%. This approval highlights the broader health benefits of GLP-1 drugs like Ozempic, which are already used for diabetes and weight loss, while Novo Nordisk faces growing competition and ongoing Medicare drug price negotiations. Read more: https://lnkd.in/d8hQYpbp #fdaapproval #fda #ozempic #nephrology #medicalresearch #clinicalresearch #medicalupdate #medicalupdates #medicalnews #pharmaupdate #pharmaupdates #pharmanews #healthcareupdate #healthcareupdates #healthcarenews #hcp #scientificupdate #clinicalguideline #clinicalguidelines #medicalguideline #medicalguidelines #carbonbrandsolutions

Revolutionizing Diabetes and Obesity Management with GLP-1 Receptor Agonists GLP-1 receptor agonists are reshaping the approach to type 2 diabetes and weight management by mimicking natural hormones to improve blood sugar control and support weight loss. These therapies address both conditions in one solution, providing patients with better outcomes and new hope. As research expands, the potential of GLP-1 therapies continues to grow across chronic disease management. For those in the pharmaceutical and healthcare industries looking to explore or partner in this rapidly evolving area. If your portfolio includes GLP-1-related products, you’re on the forefront of a powerful movement in diabetes and weight management. From innovative compounds to established therapies, the potential for GLP-1 receptor agonists in chronic disease care is unmatched. We’re here to support your success with expertise and tailored solutions in this high-impact area. Let’s connect to explore how we can help advance your GLP-1 offerings. #PharmaInnovation #GLP1 #Diabetes #WeightManagement #PartnerWithUs

Daily Critical Care Pearls #271: "Do Non-Benzo Psychotropic Medications Enhance Respiratory Depression From Opioids? 1. Benzodiazepines and Opioids Risk: Benzodiazepines are known to increase respiratory depression when taken with opioids, prompting the FDA to mandate boxed warnings for both drug classes. 2. FDA's New Focus: The FDA is investigating whether other psychotropic medications, like paroxetine and quetiapine, might have similar interactions with opioids. 3. Study Overview: A preliminary study published in JAMA explored the effects of combining oxycodone with paroxetine or quetiapine on ventilatory response in 25 healthy participants (median age 35). 4. Key Findings: Paroxetine, when combined with oxycodone, significantly reduced ventilatory response to hypercapnia, while quetiapine had no such effect. 5. Study Conclusion: The findings suggest paroxetine-opioid combinations may impair ventilatory response, but further research is needed to confirm long-term and clinical implications. 6. Next Steps: Although this small-scale study won't lead to immediate FDA warnings, it highlights the importance of further investigations into psychotropic-opioid interactions to identify potential respiratory risks. Full study can be accessed through: https://lnkd.in/drm5JCSY #criticalcare #clinicalpharmacy #medicine #pearls

On #WorldHypertensionDay, Lyrus, a leading pharmaceutical Contract Development and Manufacturing Organization (CDMO), would like to raise awareness about the global burden of #hypertension, also known as high blood pressure. Hypertension is a major risk factor for cardiovascular diseases, such as heart attacks, strokes, and heart failure, which are among the leading causes of death worldwide. According to the World Health Organization (WHO), approximately 1.28 billion adults aged 30-79 years worldwide have hypertension. At Lyrus, we recognize the critical importance of addressing this global health challenge. Through our comprehensive range of services, including formulation development and manufacturing, we are committed to supporting our pharmaceutical partners in developing innovative and effective treatments for hypertension and its associated complications. Our team of experts collaborates closely with our clients, leveraging our state-of-the-art facilities and cutting-edge technologies to advance the development of antihypertensive medications. From development to commercial manufacturing, we ensure strict adherence to quality standards and regulatory guidelines. Furthermore, we understand the importance of patient-centric approaches in managing hypertension. Our expertise in formulation development and drug delivery systems enables us to contribute to improved patient adherence and better treatment outcomes. On this World Hypertension Day, Lyrus reaffirms its commitment to supporting the global healthcare community in addressing this silent killer. Together, we can raise awareness, promote early detection, and facilitate access to effective treatments, ultimately improving the lives of millions of people affected by hypertension worldwide. #WorldHypertensionDay #RaisingAwareness #InnovativeTherapies #PatientCentricApproaches #CDMO #ThinkDesignDeliver #Lyrus  C P Bothra Hemanth bothra Rajesh Goel Elayaraja Natarajan Ramdas Velliyate Jyolsna Agnes Jose Krishna M S Raviraj Kadam

🚀 Novo Nordisk’s CagriSema Achieves Remarkable Weight Loss in Phase 3 Trial! 🌟 Novo Nordisk has successfully completed the pivotal REDEFINE 1 trial, showcasing its innovative weight-loss medication, CagriSema. This groundbreaking study revealed that participants experienced an average weight loss of 20.4%, significantly surpassing the 3.0% achieved with placebo! 🔍 Key Highlights: - Conducted over 68 weeks with 3,417 participants - CagriSema combines cagrilintide and semaglutide for enhanced efficacy - Maintains a safe and well-tolerated profile With promising results paving the way for future studies, including REDEFINE 2 targeting adults with type 2 diabetes, Novo Nordisk is committed to transforming chronic weight management. 💡 Discover how CagriSema could be a game-changer in the fight against obesity! #CagriSema #ClinicalResearches #HealthcareInnovation #NovoNordisk #ObesityManagement #Pharma #PharmaceuticalCompanies #WeightLoss #MarketAccess #MarketAccessToday

#GLP1's are everywhere. It feels like everyone and their mother is blissfully and religiously injecting themselves with one of these miracle drugs for diabetes or weight loss. But what is actually happening in the real world? It turns out that people don't stay on these drugs despite the sensational results... Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research. (Hearn EB, Sherman JJ. Diabetes Spectr. 2021 Jan;34(1):73-75) Can we be curious about why? General injection-site reactions (e.g., erythema, pain, or rash) have been reported with all of the commercially available GLP-1 receptor agonists (i.e., exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) All of them (exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) cause injection site reactions like erythema , pain, rash . How might adherence change if we treated injection site reactions? Imagine what it might feel like for a patient to receive care these these symptoms that we, on the medical side, tend to label as insignificant. What could a Thimble Recover patch do for medication adherence and for the patient experience? Would you want your injections to come with solutions to alleviate the discomfort? #stickwithcompassion